Adenoviral vectors for gene therapy

Molecular Biotechnology

Volumn 36, Issue 1, 2007, Pages 71-80

  Douglas, Joanne T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; GENES; IMMUNIZATION; VIRUSES;

ADENOVIRAL VECTORS; CELLULAR RECEPTORS; SURFACE RECEPTORS;

GENETIC ENGINEERING;

ADENOVIRUS VECTOR;

ARTICLE; GENE THERAPY; GENE TRANSFER; IMMUNE RESPONSE; IN VIVO STUDY; VIRUS CAPSID; ADENOVIRUS; ANIMAL; CHEMISTRY; GENE VECTOR; GENETICS; HUMAN; METABOLISM; REVIEW; VIRUS INFECTION;

HUMAN ADENOVIRUS;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS;

EID: 34848904829     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12033-007-0021-5     Document Type: Article

References (67)

1. Berkner, K. L. (1988). Development of adenovirus vectors for the expression of heterologous genes. Biotechniques, 6, 616-629.
2. ICTVdB - The Universal Virus Database, http://www.ncbi.nlm.nih.gov/ ICTVdb/ICTVdB/.
3. Shenk , T. (1996). Adenoviridae: The viruses and their replication. In B. N. Fields, et al. (Eds.), Fields virology (pp. 2111-2148). Philadelphia, PA, State: Lippincott-Raven Publishers.
4. Kovesdi, I., Brough, D. E., Bruder, J. T., & Wickham, T. J. (1997). Adenoviral vectors for gene transfer. Currrent Opinion in Biotechnology, 8, 583-589.
5. Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science, 275, 1320-1323.
6. Tomko, R. P., Xu, R., & Philipson, L. (1997). HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proceedings of the National Academy of Sciences of the United States of America, 94, 3352-3356.
7. Henry, L. J., Xia, D., Wilke, M. E., Deisenhofer, J., & Gerard, R. D. (1994). Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. Journal of Virology, 68, 5239-5246.
8. Louis, N., Fender, P., Barge, A., Kitts, P., & Chroboczek, J. (1994). Cell-binding domain of adenovirus serotype 2 fiber. Journal of Virology, 68, 4104-4106.
9. Leon, R. P., Hedlund, T., Meech, S. J., Li, S., Schaack, J., Hunger, S. P., Duke, R. C., & DeGregori, J. (1998). Adenoviral-mediated gene transfer in lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 95, 13159-13164.
10. Wang, X., & Bergelson, J. M. (1999). Coxsackievirus and adenovirus receptor cytoplasmic and transmembrane domains are not essential for coxsackievirus and adenovirus infection. Journal of Virology, 73, 2559-2562.
11. Bai, M., Harfe, B., & Freimuth, P. (1993). Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. Journal of Virology, 67, 5198-5205.
12. Wickham, T. J., Mathias, P., Cheresh, D. A., & Nemerow, G. R. (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell, 73, 309-319.
13. Danthinne, X., & Imperiale, M. J. (2000). Production of first generation adenovirus vectors: A review. Gene Therapy, 7, 1707-1714.
14. Chinnadurai, G., Chinnadurai, S., & Brusca, J. (1979). Physical mapping of a large-plaque mutation of adenovirus type 2. Journal of Virology, 32, 623-628.
15. McGrory, W. J., Bautista, D. S., & Graham, F. L. (1988). A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology, 163, 614-617.
16. Bett, A. J., Haddara, W., Prevec, L., & Graham, F. L. (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proceedings of the National Academy of Sciences of the United States of America, 91, 8802-8806.
17. Chartier, C., Degryse, E., Gantzer, M., Dieterle, A., Pavirani, A., & Mehtali, M. (1996). Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. Journal of Virology, 70, 4805-4810.
18. Crouzet, J., Naudin, L., Orsini, C., Vigne, E., Ferrero, L., Le Roux, A., Benoit, P., Latta, M., Torrent, C., Branellec, D., Denefle, P., Mayaux, J. F., Perricaudet, M., & Yeh, P. (1997). Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proceedings of the National Academy of Sciences of the United States of America, 94, 1414-1419.
19. He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., & Vogelstein, B. (1998). A simplified system for generating recombinant adenoviruses. Proceedings of the National Academy of Sciences of the United States of America, 95, 2509-2514.
20. Graham, F. L., Smiley, J., Russell, W. C., & Nairn, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. The Journal of General Virology, 36, 59-74.
21. Lochmuller, H., Jani, A., Huard, J., Prescott, S., Simoneau, M., Massie, B., Karpati, G., & Acsadi, G. (1994). Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (delta E1 + delta E3) during multiple passages in 293 cells. Human Gene Therapy, 5, 1485-1491.
22. Fallaux, F. J., Bout, A., van der Velde, I., van den Wollenberg, D. J., Hehir, K. M., Keegan, J., Auger, C., Cramer, S. J., van Ormondt, H., van der Eb, A. J., Valerio, D., & Hoeben, R. C. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Human Gene Therapy, 9, 1909-1917.
23. Gao, G. P., Engdahl, R. K., & Wilson, J. M. (2000). A cell line for high-yield production of E1-deleted adenovirus vectors without the emergence of replication-competent virus. Human Gene Therapy, 11, 213-219.
24. Shabram P., Vellekamp G., & Scandella C. (2002). Purification of adenovirus. In D. T. Curiel & J. T. Douglas (Eds.), Adenoviral vectors for gene therapy (pp. 167-204). New York, NY, State: Academic Press.
25. Mittereder, N., March, K. L., & Trapnell, B. C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. Journal of Virology, 70, 7498-7509.
26. Maizel, J. V. Jr., White, D. O., & Scharff, M. D. (1968). The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology, 36, 115-125.
27. Curiel, D. T., & Douglas, J. T. (2002). Adenoviral vectors for gene therapy. New York, NY, State: Academic Press.
28. Vectors used in gene therapy clinical trials (2006). In Gene therapy clinical trials worldwide. http://www.wiley.co.uk/genmed/clinical/.
29. Roth, J. A. (2006). Adenovirus p53 gene therapy. Expert Opinion on Biological Therapy, 6, 55-61.
30. Gingrich, J. R. (1999). Protocol 9909-338. A tolerance and efficacy study of neoadjuvant intraprostatic GTx-001 followed by radical prostatectomy in patients with locally advanced prostate cancer. http://www4.od.nih.gov/oba/rac/ PROTOCOL.pdf.
31. Deshane, J., Siegal, G. P., Alvarez, R. D., Wang, M. H., Feng, M., Cabrera, G., Liu, T., Kay, M., & Curiel, D. T. (1995). Targeted tumor killing via an intracellular antibody against erbB-2. The Journal of Clinical Investigation, 96, 2980-2989.
32. Alvarez, R. D., Barnes, M. N., Gomez-Navarro, J., Wang, M., Strong, T. V., Arafat, W., Arani, R. B., Johnson, M. R., Roberts, B. L., Siegal, G. P., & Curiel, D. T. (2000). A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clinical Cancer Research, 6, 3081-3087.
33. Peng, Z. (2005). Current status of Gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers. Human Gene Therapy, 16, 1016-1027.
34. Wilson, J. M. (2005). Gendicine: The first commercial gene therapy product. Human Gene Therapy, 16, 1014-1015.
35. Gabrilovich, D. I. (2006). INGN 201 (Advexin): Adenoviral p53 gene therapy for cancer. Expert Opinion on Biological Therapy, 6, 823-832.
36. Gao, M. H., Lai, N. C., McKirnan, M. D., Roth, D. A., Rubanyi, G. M., Dalton, N., Roth, D. M., & Hammond, H. K. (2004). Increased regional function and perfusion after intracoronary delivery of adenovirus encoding fibroblast growth factor 4: Report of preclinical data. Human Gene Therapy, 15, 574-587.
37. Shiver, J. W., Fu, T. M., Chen, L., Casimiro, D. R., Davies, M. E., Evans, R. K., Zhang, Z. Q., Simon, A. J., Trigona, W. L., Dubey, S. A., Huang, L., Harris, V. A., Long, R. S., Liang, X., Handt, L., Schleif, W. A., Zhu, L., Freed, D. C., Persaud, N. V., Guan, L., Punt, K. S., Tang, A., Chen, M., Wilson, K. A., Collins, K. B., Heidecker, G. J., Fernandez, V. R., Perry, H. C., Joyce, J. G., Grimm, K. M., Cook, J. C., Keller, P. M., Kresock, D. S., Mach, H., Troutman, R. D., Isopi, L. A., Williams, D. M., Xu, Z., Bohannon, K. E., Volkin, D. B., Montefiori, D. C., Miura, A., Krivulka, G. R., Lifton, M. A., Kuroda, M. J., Schmitz, J. E., Letvin, N. L., Caulfield, M. J., Bett, A. J., Youil, R., Kaslow, D. C., & Emini, E. A. (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature, 415, 331-335.
38. Sullivan, N. J., Geisbert, T. W., Geisbert, J. B., Xu, L., Yang, Z. Y., Roederer, M., Koup, R. A., Jahrling, P. B., & Nabel, G. J. (2003). Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature, 424, 681-684.
39. Santosuosso, M., McCormick, S., Zhang, X., Zganiacz, A., & Xing, Z. (2006). Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infection and Immunity, 74, 4634-4643.
40. Plog, M. S., Guyre, C. A., Roberts, B. L., Goldberg, M., St George, J. A., & Perricone, M. A. (2006). Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery. Human Gene Therapy, 17, 705-716.
41. Miller, C. R., Buchsbaum, D. J., Reynolds, P. N., Douglas, J. T., Gillespie, G. Y., Mayo, M. S., Raben, D., & Curiel, D. T. (1998). Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Research, 58, 5738-5748.
42. Kim, M., Zinn, K. R., Barnett, B. G., Sumerel, L. A., Krasnykh, V., Curiel, D. T., & Douglas, J. T. (2002). The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. European Journal of Cancer, 38, 1917-1926.
43. Zabner, J., Freimuth, P., Puga, A., Fabrega, A., & Welsh, M. J. (1997). Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. The Journal of Clinical Investion, 100, 1144-1149.
44. Nalbantoglu, J., Pari, G., Karpati, G., & Holland, P. C. (1999). Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Human Gene Therapy, 10, 1009-1019.
45. Tillman, B. W., Gruijl, T. D., Bakker, S. A., Scheper, R. J., Pinedo, H. M., Curiel, T. J., Gerritsen, W. R., & Curiel, D. T. (1999). Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. Journal of Immunology, 162, 6378-6383.
46. Barnett, B. G., Crews, C. J., & Douglas, J. T. (2002). Targeted adenoviral vectors. Biochimica et Biophysica Acta, 1575, 1-14.
47. Douglas, J. T., Rogers, B. E., Rosenfeld, M. E., Michael, S. I., Feng, M., & Curiel, D. T. (1996). Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotechnology, 14, 1574-1578.
48. Dmitriev, I., Kashentseva, E., Rogers, B. E., Krasnykh, V., & Curiel, D. T. (2000). Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. Journal of Virology, 74, 6875-6884.
49. Krasnykh, V. N., Douglas, J. T., & van Beuschem, V. W. (2000). Genetic targeting of adenoviral vectors. Molecular Therapy, 1, 391-405.
50. Kanerva, A., Mikheeva, G. V., Krasnykh, V., Coolidge, C. J., Lam, J. T., Mahasreshti, P. J., Barker, S. D., Straughn, M., Barnes, M. N., Alvarez, R. D., Hemminki, A., & Curiel, D. T. (2002). Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clinical Cancer Research, 8, 275-280.
51. Mizuguchi, H., Hayakawa, T. (2002). Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene, 285, 69-77.
52. Dmitriev, I., Krasnykh, V., Miller, C. R., Wang, M., Kashentseva, E., Mikheeva, G., Belousova, N., & Curiel, D. T. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. Journal of Virology, 72, 9706-9713.
53. Krasnykh, V., Belousova, N., Korokhov, N., Mikheeva, G., & Curiel, D. T. (2001). Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. Journal of Virology, 75, 4176-4183.
54. Belousova, N., Korokhov, N., Krendelshchikova, V., Simonenko, V., Mikheeva, G., Triozzi, P. L., Aldrich, W. A., Banerjee, P. T., Gillies, S. D., Curiel, D. T., & Krasnykh, V. (2003). Genetically targeted adenovirus vector directed to CD40-expressing cells. Journal of Virology, 77, 11367-11377.
55. Belousova, N., Korokhov, N., Krendelshchikova, V., Simonenko, V., Mikheeva, G., Triozzi, P. L., Aldrich, W. A., Banerjee, P. T., Gillies, S. D., Curiel, D. T., & Krasnykh, V. (2003). Genetically targeted adenovirus vector directed to CD40-expressing cells. Journal of Virology, 77, 11367-11377.
56. Barnett, B. G., Tillman, B. W., Curiel, D. T., & Douglas, J. T. (2002). Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. Molecular Therapy, 6, 377-385.
57. Lyons, M., Onion, D., Green, N. K., Aslan, K., Rajaratnam, R., Bazan-Peregrino, M., Phipps, S., Hale, S., Mautner, V., Seymour, L. W., & Fisher, K. D. (2006). Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Molecular Therapy, 14, 118-128.
58. Shayakhmetov, D. M., Gaggar, A., Ni, S., Li, Z. Y., & Lieber, A. (2005). Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. Journal of Virology, 79, 7478-7491.
59. Fechner, H., Haack, A., Wang, H., Wang, X., Eizema, K., Pauschinger, M., Schoemaker, R., Veghel, R., Houtsmuller, A., Schultheiss, H. P., Lamers, J., & Poller, W. (1999). Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Therapy, 6, 1520-1535.
60. Shayakhmetov, D. M., Li, Z. Y., Ni, S., & Lieber, A. (2002). Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Research, 62, 1063-1068.
61. Brenner, M. (1999). Gene transfer by adenovectors. Blood, 94, 3965-3967.
62. Young, L. S., & Mautner, V. (2001). The promise and potential hazards of adenovirus gene therapy. Gut, 48, 733-736.
63. Geddes, B. J., Harding, T. C., Hughes, D. S., Byrnes, A. P., Lightman, S. L., Conde, G., & Uney, J. B. (1996). Persistent transgene expression in the hypothalamus following stereotaxic delivery of a recombinant adenovirus: suppression of the immune response with cyclosporin. Endocrinology, 137, 5166-5169.
64. Jooss, K., Turka, L. A., & Wilson, J. M. (1998). Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Therapy, 5, 309-319.
65. Lemckert, A. A., Grimbergen, J., Smits, S., Hartkoorn, E., Holterman, L., Berkhout, B., Barouch, D. H., Vogels, R., Quax, P., Goudsmit, J., & Havenga, M. J. (2006). Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: Manufacture on PER.C6 cells, tropism and immunogenicity. The Journal of General Virology, 87, 2891-2899.
66. Kobinger, G. P., Feldmann, H., Zhi, Y., Schumer, G., Gao, G., Feldmann, F., Jones, S., & Wilson, J. M. (2006). Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology, 346, 394-401.
67. Roberts, D. M., Nanda, A., Havenga, M. J., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., Lifton, M. A., Lemckert, A. A., Holterman, L., Chen, B., Dilraj, A., Carville, A., Mansfield, K. G., Goudsmit, J., & Barouch, D. H. (2006). Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature, 441, 239-243.